Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Empowerpharm Awaits Phase 2 Trial for Groundbreaking Treatment for Social Anxiety Disorder
Details : EmpowerCBD (cannabidiol oral solution) is a CB1 receptor negative allosteric modulator. It is being evaluated for the treatment of social anxiety disorder.
Product Name : EmpowerCBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 03, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EmpowerPharm: Positive Phase 2 Results for CBD in Social Anxiety Disorder
Details : EmpowerCBD (cannabidiol oral solution) is a CB1 receptor negative allosteric modulator. It is being evaluated for the treatment of social anxiety disorder.
Product Name : EmpowerCBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 06, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable